Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.50 |
| ▸ | MGAM | O43451 | 8/20 | 0.50 |
| ▸ | SI | P14410 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LCT | P09848 | 1/20 | 0.46 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.46 |
| ▸ | UGCG | Q16739 | 3/20 | 0.46 |
| ▸ | AGL | P35573 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camiglibose SCHEMBL19510347 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL6794338 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL1201508 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL4604473 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL3952283 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5238483 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL758524 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5186895 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL2052995 | 1.00 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL37446 | 0.99 | GAA (0.49) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5643874-A | ANTIOBESITY AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| EP-1148054-A1 | Thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| EP-1127882-A1 | Tetrazole compounds as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1125579-A2 | Uses of agrp-melanocortin receptor binding modulating compounds | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001024748-A1 | ABSORBENT ARTICLE HAVING BARRIER SHEET AGAINST THE MIGRATION OF THE SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-1088819-A2 | 6-azauracil derivatives as thyroid receptor ligands | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000069481-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069485-A1 | ABSORBENT ARTICLE WITH SKIN CARE COMPOSITION | THE PROCTER & GAMBLE COMPANY (US) | 2000-11-23 | — | — | WO | disclosed |
| US-5643874-A | ANTIOBESITY AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | GAA 2064/4885MGAM 3560/4885SI 2899/4885 |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | GAA 383/4885MGAM 713/4885SI 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.